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The  SAMBA  HIV-1  Qual  Whole  Blood  Test  is  a nucleic  acid–based  ampliﬁcation  assay  for the qualitative
detection  of HIV-1  in whole  blood  of adults  or infants.  The test  can  be run  on  either the  semi-automated
SAMBA  I system  for clinical  use or the  fully  automated,  including  readout,  SAMBA  II system  for  point-of-
care  use  in resource-limited  settings.  We  have  assessed  the  performance  characteristics  of  the  SAMBA
HIV-1  Qual  Whole  Blood  Test  on  SAMBA  I and  SAMBA  II.  The  limit  of  detection  obtained  for  the  two
tests  were  518 IU/ml  and 399  copies/ml  on SAMBA  I and  457  IU/ml  and  433  copies/ml  on  SAMBA  II.  Test
speciﬁcity  on  both  systems  was 100%  with  a panel  of 503  HIV-1  negative  samples.  Evaluation  of  testiagnosis
oint-of-care
arly infant diagnosis
reproducibility  showed  100%  concordance  with  expected  gold  standard  results  as  well  as 100%  agreement
between  operators,  days,  and  runs  as  well  as  within  runs  on both  SAMBA  I and  SAMBA  II. Our  results  thus
show  that the  SAMBA  HIV-1  Qual  Whole  Blood  Test  performs  equivalently  on  SAMBA  I and  SAMBA  II,  and
also suggest  that  the  test  is  suitable  for  implementation  in medium-throughput  clinical  facilities  (SAMBA
I) or low-throughput  point-of-care  (POC)  settings  (SAMBA  II) in resource-poor  regions.
©  2016  The  Authors.  Published  by  Elsevier  B.V.  This  is  an  open  access  article  under the  CC  BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).. Introduction
The growth in the implementation of efﬁcacious prevention of
other-to-child transmission programs worldwide has led to the
rospect that paediatric infection with human immunodeﬁciency
irus (HIV) can be eliminated. The achievement of this goal, how-
ver, will require further progress in testing exposed infants and
he initiation of antiretroviral therapy (ART) as soon as infection
s detected. An estimated 240,000 infants were newly infected in
013, with 89% of these cases occurring in Africa (WHO, 2014a). In
008, the Children with HIV Early ART (CHER) study showed that
nitiation of ART before 12 weeks of age reduced the mortality of
Abbreviations: HIV, human immunodeﬁciency virus; ART, antiretroviral ther-
py;  WHO, World Health Organization; EID, early infant diagnosis; NAAT, nucleic
cid ampliﬁcation test; DBS, dried blood spot; PCR, polymerase chain reaction;
OC,  point-of-care; LOD, limit of detection; HCV, hepatitis C virus; HTLV, human
-lymphotropic virus; CI, conﬁdence interval.
∗ Corresponding author at: Department of Haematology, University of Cambridge,
cience Village, Chesterford Research Park, Great Chesterford, CB10 1XL, UK.
E-mail address: hl207@cam.ac.uk (H.H. Lee).
ttp://dx.doi.org/10.1016/j.jviromet.2016.08.017
166-0934/© 2016 The Authors. Published by Elsevier B.V. This is an open access article 
/).infected infants by 76% and slowed the progression of disease by
75% by improving long-term viral suppression and weight for age
scores (Violari et al., 2008). The 2013 World Health Organization
(WHO) guidelines state that all infants born to HIV-positive moth-
ers should be tested for HIV with a molecular test within the ﬁrst
2 months of life and that ART should be initiated immediately on
diagnosis (WHO, 2013a). Although early infant diagnosis (EID) is
expanding, only 44% of exposed infants received a genomic diag-
nostic test in the 88 low and middle-income countries reporting to
WHO in 2013 and only 23% were receiving ART (WHO, 2014a).
Persistence of maternal antibodies in infants up to 18 months of
age necessitates the use of nucleic acid ampliﬁcation tests (NAATs)
for the detection of HIV-1 proviral DNA or RNA as the most reli-
able HIV-1 diagnostic tools in infants (Creek et al., 2008). Current
gold standard EID algorithms rely on dried blood spots (DBSs) and
NAATs such as those based on the polymerase chain reaction (PCR),
(Chohan et al., 2011) and they are restricted to a few centralised
laboratories in each resource-poor country as a result of the size,
expense, complexity of the equipment and the demanding testing
protocols (Hsiao et al., 2013). Access to EID is thus expanding in
urban areas but often entails substantial delays elsewhere (WHO,
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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013b). Even in the best of circumstances, it can take 4 weeks
or results to be returned to remote sites, and in some settings
t can take 2 months or longer (Sutcliffe et al., 2014). Given that
any women must travel to a health facility with their 6-week-old
nfants for testing (and standard vaccinations) and then return 2–4
eeks later for the results, mothers and their infants are often lost
o follow-up between testing and result availability (Rollins et al.,
009; Hassan et al., 2012; Chiduo et al., 2013), with the opportu-
ity for diagnosis and treatment being either missed or delayed.
ccording to a 2009 report by the Clinton HIV/AIDS Initiative, an
verage of 53% of infants are lost to follow-up after testing, with
ore than 70% of this loss occurring before the initiation of ART, as
 result of the poor quality of testing services and long turnaround
imes (Initiative, 2009). In the absence of EID and immediate initi-
tion of ART, mortality peaks at 3–4 months of age (Bourne et al.,
009; Innes et al., 2014) and 35% of HIV-1-infected infants die in
he 1st year of life, with this value increasing to 53% in the 2nd year
Newell et al., 2004).
A NAAT study in South Africa of perinatally exposed infants
ound that the Roche COBAS AmpliPrep/COBAS TaqMan CAP/CTM
nd Gen-Probe Aptima assays for HIV-1 identiﬁed 76.3% of infected
nfants at birth and were 100% speciﬁc (Lilian et al., 2012). The
mplicor HIV DNA PCR assay (Roche Molecular Systems, v.1)
howed test sensitivities of 68.4% and 96.0%, with infants at birth
nd 4 weeks of age, respectively. Testing at birth with a high-
erformance, simple, point-of-care (POC) nucleic acid test would
e expected to expand coverage of EID as well as to reduce the
isk of loss to follow-up and to promote early initiation of ART
y minimizing the delay between testing and diagnosis. A sim-
le, fully automated, sample in – result out POC system would be
ptimal for ease of use and efﬁcacy in health care settings without
aboratory-trained staff.
Several POC technologies for EID are under development, but
ew are at an advanced stage (UNITAID, 2014). The SAMBA (Simple
Mpliﬁcation Based Assay) HIV-1 Qual Whole Blood Test (Diagnos-
ics for the Real World) has been developed as a simple, heat-stable,
nd robust assay for the qualitative detection of HIV-1 RNA or DNA
n whole blood in order to aid the diagnosis of HIV-1 infection
n infants and adults in resource-limited regions with prevalence
f infection >5% (Dineva et al., 2005; Lee et al., 2010). The test
s intended for use in clinical or POC settings with whole blood
btained from a ﬁnger or heel prick as a sample, which simpli-
es specimen collection and shortens the overall test time by not
equiring processing and drying as for DBS samples. The SAMBA
IV-1 Qual Whole Blood Test can be processed with the SAMBA I
r SAMBA II systems. The SAMBA I system is appropriate for near-
atient testing, given that it requires two instruments and ﬁve
imple manual steps to process batches of up to six samples. The
AMBA I system for viral load testing (Ritchie et al., 2014) has been
uccessfully implemented at six Médecins sans Frontières sites in
alawi and Uganda since August 2013, where over 47,000 sam-
les have been tested to date with an invalid rate of just 0.39%
unpublished data). The SAMBA II system is fully automated and
esigned for POC settings. The chemistry (including primers) is the
ame as for SAMBA I, but the cartridges are processed automatically
nd the results optically obtained by the instrument. The SAMBA
rimer sequences are 22 bases in length and target the highly con-
erved LTR region of the HIV genome. The SAMBA II instrument has
 small footprint, is easily transportable between sites, and does
ot require a desktop computer. Given that the reagents are stable
or up to 1 month at 55◦C and for up to 9 months at 2◦ to 37◦C, no
old-chain transport or refrigerated storage of reagents is required.
he main beneﬁt of the SAMBA platform over current DBS testing
lgorithms is that samples can be tested within 2 h, with the conse-
uence that patients can wait on-site for their results and receive
ppropriate treatment or counselling in the same visit. In addition,l Methods 237 (2016) 143–149
as alluded to above, the use of whole blood obtained from a ﬁnger or
heel prick does not require skilled phlebotomists or centrifugation
equipment, which are often not available at POC settings.
We have here assessed the laboratory performance of the
SAMBA HIV-1 Qual Whole Blood Test together with both SAMBA
I and SAMBA II systems.
2. Materials and methods
2.1. Panels and samples
Panel members for determination of the limit of detection
(LOD) were prepared with the WHO  2nd HIV-1 RNA International
Standard [code no. 97/650; National Institute for Biological Stan-
dards and Control (NIBSC), Potter’s Bar, UK] and the HIV-1 VQA
RNA Quantiﬁcation Standard [contract no. HHSN272201200023C;
NIAID Virology Quality Assurance (VQA) Program, Rush University,
Chicago, IL, USA]. The WHO  standard stock was provided in the
amount of 363,078 IU per vial and was  reconstituted in 1 ml  of
sterile molecular biology grade water. The VQA standard was pro-
vided in a volume of 1 ml  at a concentration of 150,000 copies/ml.
Six-member in-house panels containing 10 times the required
concentrations (10,000, 8000, 6000, 4000, 2000, and 0 IU/ml or
copies/ml) were prepared by dilution of each standard in a pool of
normal commercially sourced plasma negative for HIV-1 RNA, anti-
bodies to HIV-1 or to HIV-2, antibodies to hepatitis C virus (HCV),
HCV RNA, and hepatitis B surface antigen as well as nonreactive in
a screening test for syphilis (Innovative Research, Novi, MI,  USA).
Panel members were apportioned for single-use only and stored at
−80 ◦C until use. Immediately before use, the panels were thawed
and diluted 1:10 in normal HIV-1 negative whole blood (Innovative
Research) for production of whole-blood panels containing 1000,
800, 600, 400, 200, and 0 IU/ml or copies/ml.
Seroconversion panels were obtained from SeraCare Life Sci-
ences (Milford, MA,  USA). Subtyped samples were obtained from
Rush University, the External Quality Assurance Program Oversight
Laboratory (Durham, NC, USA), the Virology Department at the Uni-
versity of Erlangen (Germany), SeraCare Life Sciences, BioQControl
(Rijswijk, the Netherlands), and NIBSC. In addition, surplus clinical
samples from previous studies that had been obtained from The
Royal London Hospital (London, UK), St Thomas’ Hospital (London,
UK), and the Namibia National Blood Service were used (Lee et al.,
2010; Ritchie et al., 2014).
For determination of assay speciﬁcity, fresh HIV-1-negative
whole-blood samples were kindly provided by M. Schmidt of the
German Red Cross (Frankfurt, Germany) or were obtained from
SeraCare Life Sciences. Plasma samples positive for HIV-2 were
obtained from the University of Erlangen; those positive for human
T-lymphotropic virus (HTLV)-I, HTLV-II, Epstein-Barr virus, HBV,
HCV, or antinuclear antibodies plus those collected from individ-
uals with multiple myeloma or multiple sclerosis were obtained
from SeraCare Life Sciences; and those collected from individuals
with systemic lupus erythematosus, multiple sclerosis or positive
for rheumatoid factor were obtained from Innovative Research.
Bilirubin and triglycerides were obtained from Sigma (Gilling-
ham, UK), and human DNA was from Promega (Southampton, UK).
Antiretroviral drugs were kindly provided by G. Brook (Central Mid-
dlesex Hospital, London, UK). The plasma panels were all diluted
1:5 in HIV negative whole blood prior to use.
2.2. Sample preparation, ampliﬁcation, and detectionFor the SAMBA I system, automated sample preparation (isola-
tion of nucleic acid from 100 l of whole blood) is performed with
the SAMBAprep instrument (Fig. 1A) and both ampliﬁcation and
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Fig. 1. (a) SAMBA I system. SAMBAprep (left) for sample preparation and SAM-
BAamp (right) for ampliﬁcation & detection. The SAMBA I system is semi-automated
with few simple user interventions. The SAMBAprep is a batch process of up to 6
samples. (b) SAMBA II system. The SAMBA II system is composed of an assay Mod-
ule and a tablet control module. Each tablet can operate up to 4 assay modules
and include a tablet and printer linked by Bluetooth. Simple “sample in-result out”
system, each assay module is fully automated and modular with random access to
allow independent sample testing. (c) Negative result (d) Positive result.The SAMBA
II  system is composed of an assay Module and a tablet control module. Each tablet
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Table 2
LOD of the SAMBA HIV-1 Qual Whole Blood Test as determined with the HIV-1 VQA
RNA Quantiﬁcation Standard and the SAMBA I or SAMBA II system.
Concentration
(copies/ml)
Number
tested
Percent positive
with SAMBA I
Percent positive
with SAMBA II
1000 24 100 100
800  24 100 100
600  24 100 100
400  24 88 83an operate up to 4 assay modules. Simple “sample in-result out” system, each assay
odule is fully automated and modular with random access to allow independent
ample testing.
etection of the target nucleic acid are performed with the semi-
utomated SAMBAamp instrument (Fig. 1B), which requires ﬁve
imple manual steps including reading of the visual results. The
resence of a control and test line on the dipstick indicates a valid
est and a positive result, respectively, whereas the absence of the
est line indicates a negative result and the absence of both lines
ndicates an invalid test (Fig. 1C). In the SAMBA II system, sample
reparation, ampliﬁcation, and detection as well as reading and
nterpretation of the results are fully automated. The test is carried
able 1
OD of the SAMBA HIV-1 Qual Whole Blood Test as determined with the WHO  2nd
IV-1 RNA International Standard and the SAMBA I or SAMBA II system.
Concentration
(IU/ml)
Number
tested
Percent positive
with SAMBA I
Percent positive
with SAMBA II
1000 24 100 100
800  24 100 100
600  24 100 100
400  24 71 83
200  24 50 50
0  24 0 0200  24 75 71
0  24 0 0
out in the SAMBA II Assay Module under the control of the SAMBA
II Tablet Module (Fig. 1B).
The SAMBA HIV-1 Qual Whole Blood Test relies on two  sets of
primers and probes to amplify the long terminal repeat (LTR) region
of the HIV-1 genome and the integrated internal control. The inter-
nal control is included in the sample preparation cartridge and is
extracted, ampliﬁed, and detected alongside each sample to control
for false negative results.
3. Results
3.1. LOD
The LOD of the SAMBA HIV-1 Qual Whole Blood Test as per-
formed with the SAMBA I and SAMBA II systems was determined
by testing dilutions of the WHO  2nd HIV-1 RNA International
Standard (0–1000 IU/ml) and the HIV-1 VQA RNA Quantiﬁcation
Standard (0–1000 copies/ml). Testing was performed by three
operators, with each operator using a different lot of reagents
and eight replicates of each dilution. Probit analysis yielded LOD
values of 518 IU/ml [95% conﬁdence interval (CI), 422–615 IU/ml]
and 399 copies/ml (95% CI, 311–487 copies/ml) for SAMBA I and
457 IU/ml (95% CI, 369–545 IU/ml) and 433 copies/ml (95% CI,
341–525 copies/ml) for SAMBA II (Tables 1 and 2).
3.2. Seroconversion sensitivity
The sensitivity of the SAMBA HIV-1 Qual Whole Blood Test was
evaluated by testing sequential plasma specimens from 10 HIV-1
seroconversion panels diluted in negative whole blood. The results
for the 10 panels obtained with the SAMBA I and SAMBA II sys-
tems are shown in Table 3 together with those obtained with other
nucleic acid tests as provided by the panel supplier (corrected for
the dilution factor). Thirty of the 60 samples tested were positive
and 30 negative in both SAMBA I and SAMBA II. All samples with a
viral load of ≥156 copies/ml were positive in both systems. Of the
30 samples that tested negative, four had detectable virus (accord-
ing to the quantiﬁcation derived from the supplier information)
but at a level below the LOD for the SAMBA HIV-1 Qual Whole
Blood Test: PRB949-2 (100 copies/ml), PRB956-2 (142 copies/ml),
PRB962-3 (152 copies/ml), and PRB968-5 (130 copies/ml).
3.3. Detection of HIV-1 subtypes and groups
The ability of the SAMBA HIV-1 Qual Whole Blood Test to detect
different HIV-1 subtypes and groups was evaluated by testing a
minimum of 10 clinical specimens for common Group M subtypes A
(n = 10), B (n = 10), C (n = 11), D (n = 10), CRF01 AE (n = 12), F (n = 10),
CRF02 AG (n = 12), and G (n = 11) in SAMBA I and SAMBA II. For the
rarer Group M subtypes, two  clinical specimens of subtype K and
three of subtype J as well as 10 replicates of one sample for sub-
type H were tested. Fourteen clinical specimens for Group O and
10 replicates of one Group N sample were also tested. Each sample
was diluted in negative whole blood to a concentration of ∼3x LOD
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Table 3
Seroconversion sensitivity of the SAMBA HIV-1 Qual Whole Blood Test as performed
with the SAMBA I or SAMBA II system.
Panel member Bleed date Comparator
NAAT (copies/ml)
SAMBA I SAMBA II
PRB949-1 0 BLDa Negative Negative
PRB949-2 6 100a Negative Negative
PRB949-3 9 2000a Positive Positive
PRB949-4 18 120,000a Positive Positive
PRB950-1 0 BLDb Negative Negative
PRB950-2 18 14,000b Positive Positive
PRB950-3 21 100,000b Positive Positive
PRB950-4 28 100,000b Positive Positive
PRB956-1 0 BLDc Negative Negative
PRB956-2 40 142c Negative Negative
PRB956-3 42 1440c Positive Positive
PRB956-4 47 32,000c Positive Positive
PRB956-5 50 60,000c Positive Positive
PRB962-1 0 <50d Negative Negative
PRB962-2 2 <50d Negative Negative
PRB962-3 7 152e Negative Negative
PRB962-4 9 1540e Positive Positive
PRB962-5 14 140,000e Positive Positive
PRB962-6 17 2,400,000e Positive Positive
PRB963-1 0 <50d Negative Negative
PRB963-2 2 <50d Negative Negative
PRB963-3 7 <50d Negative Negative
PRB963-4 9 <50d Negative Negative
PRB963-5 14 1560e Positive Positive
PRB963-6 17 19,200e Positive Positive
PRB963-7 21 124,000e Positive Positive
PRB964-1 0 <50d Negative Negative
PRB964-2 3 <50d Negative Negative
PRB964-3 10 <50d Negative Negative
PRB964-4 15 400e Positive Positive
PRB964-5 17 4800e Positive Positive
PRB964-6 22 11,600e Positive Positive
PRB967-1 0 0e Negative Negative
PRB967-2 3 12e Negative Negative
PRB967-3 7 1340e Positive Positive
PRB967-4 17 118,000e Positive Positive
PRB967-5 19 1,800,000e Positive Positive
PRB967-6 24 36,000e Positive Positive
PRB968-1 0 BLDc Negative Negative
PRB968-2 3 BLDc Negative Negative
PRB968-3 8 BLDc Negative Negative
PRB968-4 10 BLDc Negative Negative
PRB968-5 15 130c Negative Negative
PRB968-6 17 1860c Positive Positive
PRB968-7 26 860,000c Positive Positive
PRB968-8 28 1,380,000c Positive Positive
PRB968-9 33 200,000c Positive Positive
PRB968-10 35 26,000c Positive Positive
PRB975-1 0 BLDc Negative Negative
PRB975-2 2 BLDc Negative Negative
PRB975-3 7 11c Negative Negative
PRB975-4 9 156c Positive Positive
PRB975-5 14 162,000c Positive Positive
PRB978-1 0 BLDc Negative Negative
PRB978-2 2 BLDc Negative Negative
PRB978-3 19 BLDc Negative Negative
PRB978-4 21 BLDc Negative Negative
PRB978-5 26 20c Negative Negative
PRB978-6 28 740c Positive Positive
PRB978-7 33 200,000c Positive Positive
BLD, below limit of detection.
a Roche PCR.
b Roche Amplicor HIV-1 Monitor.
c Abbott HIV RNA m2000.
d Roche Ultra Sensitive HIV-1 RNA.
e Roche Standard HIV-1 RNA data provided by the supplier.
Table 4
Detection of HIV-1 subtypes and groups by the SAMBA HIV-1 Qual Whole Blood Test
on SAMBA I or SAMBA II.
Subtype or
group
Number
tested
Number detected
on SAMBA I
Number detected
on SAMBA II
A 10 10/10 10/10
B  10 10/10 10/10
C  11 11/11 11/11
D  10 10/10 10/10
AE  12 12/12 12/12
F  10 10/10 10/10
AG  12 12/12 12/12
G  11 11/11 11/11
H  1 (10 replicates) 10/10 10/10
J  3 3/3 3/3
K  2 2/2 2/2
N  1 (10 replicates) 10/10 10/10
O  14 13/14a 13/14a
a The samples tested positive between 1200 and 25,000 copies/ml, with the sam-
ple not detected being MVP5180 (Group O1).
(1200 copies/ml), and Group O samples were also tested at concen-
trations of 2500, 8000, and, when possible, 25,000 copies/ml. All
subtypes and groups were detected on both SAMBA I and SAMBA
II, with the exception of one of the Group O specimens (Table 4).
3.4. Speciﬁcity evaluation
The speciﬁcity of the SAMBA HIV-1 Qual Whole Blood Test was
evaluated on SAMBA I and SAMBA II with the use of various panels
of negative samples and samples containing potentially interfer-
ing agents. A total of 503 commercially sourced HIV negative fresh
whole-blood samples collected in K3EDTA were tested on both
SAMBA I and SAMBA II. All 503 samples were negative on both
systems, yielding a speciﬁcity of 100% (95% CI, 99.4–100%).
A panel of 26 samples containing retroviruses or other blood-
borne infectious agents was evaluated for potential cross-reactivity
in the SAMBA HIV-1 Qual Whole Blood Test: HIV-2 (n = 5), HTLV-I
(n = 5), HTLV-II (n = 5), Epstein-Barr virus (n = 1), hepatitis B virus
(n = 5), and HCV (n = 5). Each sample was added to HIV-1 negative
whole blood and to whole-blood samples spiked with ∼3x LOD
(1800 IU/ml) of the WHO  3rd HIV-1 RNA International Standard. No
cross-reactivity or interference was  observed with these unspiked
or spiked samples, respectively, when tested with either the SAMBA
I or SAMBA II system.
The effect of potentially interfering substances was also evalu-
ated with panels of samples containing elevated levels of bilirubin
(200 mg/dl), triglycerides (3000 mg/dl), or human DNA (0.4 mg/dl),
each of which was added to HIV-1-negative whole blood or to
whole blood containing ∼3x LOD (1800 IU/ml) of the WHO  3rd HIV-
1 RNA International Standard. No interference was observed with
these unspiked or spiked samples on SAMBA I or SAMBA II.
The speciﬁcity of the SAMBA HIV-1 Qual Whole Blood Test was
also evaluated with specimens obtained from individuals positive
for antinuclear antibodies (n = 5) or rheumatoid factor (n = 1) or
from those diagnosed with systemic lupus erythematous (n = 1),
multiple myeloma (n = 3), or multiple sclerosis (n = 4). None of these
HIV-1 negative samples yielded a positive result on SAMBA I or
SAMBA II, however they did give a positive result after spiking with
3x LOD (1800 IU/ml) of the WHO  3rd HIV-1 RNA International Stan-
dard. These results thus showed that the presence of autoimmune
disease or serological markers of such disease did not affect the
performance of the SAMBA HIV-1 Qual Whole Blood Test.3.5. Effect of ART drugs
The effect of various ART drugs on the performance of the
SAMBA HIV-1 Qual Whole Blood Test was  assessed on SAMBA
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Table  5
Summary of reproducibility ﬁndings with a three-member panel for the SAMBA HIV-1 Qual Whole Blood Test performed on SAMBA I.
Parameter Negative (0 IU/ml) Low positive
(<50 copies/ml)
Medium positive
(5000 IU/ml)
Total number of replicates 40 40 40
Between-operator Negative
(100% agreement)
Positive
(100% agreement)
Positive
(100% agreement)
Between-day Negative
(100% agreement)
Positive
(100% agreement)
Positive
(100% agreement)
Between-run Negative
(100% agreement)
Positive
(100% agreement)
Positive
(100% agreement)
Within-run Negative
(100% agreement)
Positive
(100% agreement)
Positive
(100% agreement)
Table 6
Summary of reproducibility ﬁndings with a three-member panel for the SAMBA HIV-1 Qual Whole Blood Test performed on SAMBA II.
Parameter Negative (0 IU/ml) Low positive
(<50 copies/ml)
Medium positive
(5000 IU/ml)
Total number of replicates 40 40 40
Between-operator Negative
(100% agreement)
Positive
(100% agreement)
Positive
(100% agreement)
Between-day Negative
(100% agreement)
Positive
(100% agreement)
Positive
(100% agreement)
Between-run Negative Positive Positive
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Within-run Negative
(100% agreement)
 and SAMBA II. The following drugs were tested at levels in
xcess of 1.5 times the peak plasma concentration (Cmax): Kaivexa
abacavir/lamivudine); Atripla (efavirenz/tenofovir/emtricitabine;
aletra (lopinavir/ritonavir); Combivir (lamivudine/zidovudine);
evirapine, Ribavirin, and Saquinavir. All were tested in HIV-1-
egative whole blood and in whole blood spiked with 3x LOD
1800 IU/mL) of the WHO  3rd HIV-1 RNA International Standard. No
nterference was detected with spiked or unspiked samples tested
n SAMBA I or SAMBA II.
.6. Reproducibility
Reproducibility of the SAMBA HIV-1 Qual Whole Blood Test as
erformed on SAMBA I or SAMBA II was assessed according to
he Clinical and Laboratory Standards Institute (formerly NCCLS)
uideline (EP 12-A2, User Protocol for Evaluation of Qualitative Test
erformance: Approved Guideline, 2nd edition). A three-member
anel was tested: the WHO  3rd HIV-1 RNA International Standard
iluted in normal human whole blood at 5000 IU/ml (medium pos-
tive), the same blood without added standard (0 IU/ml, negative),
nd an HIV-1 positive clinical sample containing <50 copies/ml (low
ositive) to check for the detection of proviral-DNA. Two  operators
ested a total of 40 samples with the same lot of reagents each over
 days. There was 100% concordance between the expected results
nd the generated results with SAMBA I and SAMBA II. In addi-
ion, the SAMBA HIV-1 Qual Whole Blood Test in both SAMBA I and
AMBA II showed 100% agreement between operators, between
ays, between runs, and within runs (Tables 5 and 6).
.7. Specimen types (effect of anticoagulants)
The effect of anticoagulants (K2EDTA, K3EDTA, sodium citrate)
n the performance of the SAMBA HIV-1 Qual Whole Blood Test run
n SAMBA I or SAMBA II was assessed with a panel of 25 matched
amples (HIV-1 negative blood donations collected with each anti-
oagulant) that were either left unspiked or spiked with the WHO
rd HIV-1 RNA International Standard at 1800 IU/ml. All spiked
amples tested positive and all unspiked samples tested negative
n both SAMBA I and SAMBA II irrespective of the anticoagulant(100% agreement) (100% agreement)
Positive
(100% agreement)
Positive
(100% agreement)
type, indicating that the three anticoagulants do not interfere with
the SAMBA HIV-1 Qual Whole Blood Test.
3.8. Carryover
To examine the susceptibility of the SAMBA HIV-1 Qual Whole
Blood Test to sample carryover, we  performed 10 consecutive tests
with alternating HIV-1 negative whole blood and whole blood
containing the WHO  3rd HIV-1 RNA International Standard at
50,000 IU/ml. The samples were processed with a single channel
of SAMBAprep and SAMBAamp (SAMBA I) and with one SAMBA II
Assay Module. No carryover was  detected between runs on either
system.
3.9. Whole system failure
Whole system failure rate was assessed with 100 replicates of
negative whole blood spiked with the HIV-1 VQA RNA Quantiﬁca-
tion Standard at 1200 copies/ml (∼3x LOD). A total of 99/100 and
100/100 tests were positive on SAMBA I and SAMBA II, respectively.
4. Discussion
A key bottleneck to scaling up HIV treatment for children is
access to timely HIV diagnosis, especially for those younger than
18 months of age for whom a virological test is required. Despite
signiﬁcant investments, among 104 countries reporting in 2012,
only 35% of HIV-exposed infants underwent HIV virological testing
within the ﬁrst two months of life (WHO, 2014a). Untreated HIV
infection follows a particularly aggressive course in infants with
approximately half of HIV-infected infants dying by age 2 (Newell
et al., 2004) and peak mortality occurring between 2 to 3 months
of age (Bourne et al., 2009). Furthermore, early initiation of ART
reduces HIV-related mortality and long-term morbidity (Violari
et al., 2008). Therefore, the WHO  2013 consolidated guidelines rec-
ommend that HIV-exposed infants are tested for HIV by the time
they are 4–6 weeks of age (WHO, 2013a).
Our results demonstrate that the performance of the SAMBA
HIV-1 Qual Whole Blood Test on SAMBA I and SAMBA II is equiv-
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lent and is characterized by excellent sensitivity and speciﬁcity.
he chemistry of the two assays is identical; only the processing by
he instrument is different. In addition the SAMBA I and SAMBA II
ystems can also be used with the SAMBA HIV-1 Semi-Q Test for
onitoring of viral load, with this adaptability increasing their util-
ty at ﬁeld sites (Ritchie et al., 2014; Titchmarsh et al., 2015). Field
tudies of the performance of the SAMBA HIV-1 Qual Whole Blood
est on SAMBA I or SAMBA II with clinical samples in comparison
o a commercially available test will be reported elsewhere.
The sensitivity and speciﬁcity of diagnostics assays is critical.
he speciﬁcity of both SAMBA I and SAMBA II was 100% in a panel
f more than 500 individual whole blood samples. The RNA limit of
etection of the SAMBA I and SAMBA II tests are very similar at 399
nd 433 copies/ml respectively using an input of 100 l of whole
lood. In comparison the Abbott HIV-1 RealTime Assay has a limit
f detection of 2500 copies/ml using DBS according to the package
nsert and the Roche CAP/CTM HIV-1 Qual Test has a limit of detec-
ion of 710 copies/ml in whole blood and 1090 in DBS (Stevens et al.,
008). The more recent dual target Roche CAP/CTM Qualitative Test
2.0 has a limit of detection of 300 copies/ml using DBS according
o the package insert. However, these systems are all limited to
entralised testing facilities dependant on transfer of DBS samples
rom remote sites with the inherent problems of long turnaround
imes and high loss to follow up rates. In contrast the SAMBA sys-
ems can be used in decentralized settings to bring testing closer to
he patient. SAMBA I is already being used in Malawi and Uganda
t District hospital and health center level with greater than 90% of
he results being available on the day of testing (unpublished data)
nd SAMBA II offers further simpliﬁcation for the user allowing it
o be placed at lower level health centers and clinics. Therefore, the
AMBA sensitivity is in line with that of current centralised testing
ethods but with the added operational advantage of being suited
or remote setting at point-of-care. The SAMBA systems can there-
ore help to improve access to HIV diagnosis for infants and reduce
oss to follow up rates by providing results within two  hours.
The Treatment 2.0 initiative aims to catalyse the next phase
f HIV treatment scale-up and gives priority to providing testing
earer to the point-of-care as part of its framework. The optimal
iming of virological testing to diagnose HIV infection in infants is
 function of several factors including time of infection, test per-
ormance, mortality risk by age and retention in the testing and
reatment cascade (Lilian et al., 2012). It may  also be inﬂuenced by
perational considerations such as timing the testing to align with
he provision of routine maternal and child health services, such as
cheduled immunization visits. Therefore, current guidelines are
or testing at 4–6 weeks of age but the addition of birth testing to
etect in utero infections has been suggested (Africa, 2011; WHO,
014b). SAMBA is suited for placement both at delivery centres and
mmunisation clinics.
There are some potential limitations of the SAMBA HIV-1 Qual
hole Blood Test. The test has been evaluated only with human
hole blood specimens collected with the most commonly used
nticoagulants (K2EDTA, K3EDTA, sodium citrate). The test also
equires personnel trained with regard to the assay procedures
nd the operation of either the SAMBAprep and SAMBAamp instru-
ents (SAMBA I) or the SAMBA II Assay Module and SAMBA II
ablet Module (SAMBA II). The operators in the present study were
rained personnel experienced in performing the assays on a daily
asis. Further studies of test performance in the hands of indepen-
ent trained personnel will be described elsewhere. As with any
ther in vitro diagnostic test, the qualitative detection of HIV-1 is
ependent on several factors such as the virus concentration in the
pecimen and the quality of the specimen. Results from the SAMBA
IV-1 Qual Whole Blood Test must be interpreted in conjunction
ith other clinical and laboratory ﬁndings.l Methods 237 (2016) 143–149
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